AlatamineCAS# 41855-33-8 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 41855-33-8 | SDF | Download SDF |
| PubChem ID | 102004797 | Appearance | Powder |
| Formula | C41H45NO18 | M.Wt | 839.8 |
| Type of Compound | Sesquiterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC(=O)OCC12C(C(C3C(C14C(C(C(=O)C2OC(=O)C)C(O4)(COC(=O)C5=C(CCC(C(=O)O3)(C)O)N=CC=C5)C)OC(=O)C)(C)O)OC(=O)C6=CC=CC=C6)OC(=O)C | ||
| Standard InChIKey | WLMGYTNCKLQIDI-BLKXGXPVSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Alatamine can markedly reduce acute myocardial ischemia (AMI)-induced cardiac injury and cardiac myocyte apoptosis, improve the expression and activity of sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase (SERCA). |
| Targets | Calcium Channel | ATPase | Bcl-2/Bax |
Alatamine Dilution Calculator
Alatamine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.1908 mL | 5.9538 mL | 11.9076 mL | 23.8152 mL | 29.769 mL |
| 5 mM | 0.2382 mL | 1.1908 mL | 2.3815 mL | 4.763 mL | 5.9538 mL |
| 10 mM | 0.1191 mL | 0.5954 mL | 1.1908 mL | 2.3815 mL | 2.9769 mL |
| 50 mM | 0.0238 mL | 0.1191 mL | 0.2382 mL | 0.4763 mL | 0.5954 mL |
| 100 mM | 0.0119 mL | 0.0595 mL | 0.1191 mL | 0.2382 mL | 0.2977 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Mangiferolic acid
Catalog No.:BCN4636
CAS No.:4184-34-3
- Hesperetin-7-methyl ether
Catalog No.:BCN8501
CAS No.:
- Junicedric acid
Catalog No.:BCN7660
CAS No.:41787-69-3
- Hypecorinine
Catalog No.:BCN3298
CAS No.:41787-57-9
- H-Leu-pNA.HCl
Catalog No.:BCC2972
CAS No.:4178-93-2
- Lenvatinib (E7080)
Catalog No.:BCC1172
CAS No.:417716-92-8
- 14-Deoxyandrographolide
Catalog No.:BCN3706
CAS No.:4176-97-0
- ar-Curcumene
Catalog No.:BCN7534
CAS No.:4176-06-1
- Evonimine
Catalog No.:BCN3082
CAS No.:41758-69-4
- Dihydrophaseic acid
Catalog No.:BCN5478
CAS No.:41756-77-8
- Ophiopogonin D
Catalog No.:BCN5004
CAS No.:41753-55-3
- Ginsenoside Rb1
Catalog No.:BCN1063
CAS No.:41753-43-9
- Bezafibrate
Catalog No.:BCC4639
CAS No.:41859-67-0
- 2,3-DCPE hydrochloride
Catalog No.:BCC2384
CAS No.:418788-90-6
- PYR-41
Catalog No.:BCC4470
CAS No.:418805-02-4
- Nitrocefin
Catalog No.:BCC6544
CAS No.:41906-86-9
- Isopropyl 4-Hydroxybenzoate
Catalog No.:BCN8409
CAS No.:4191-73-5
- Trilobatin
Catalog No.:BCN5479
CAS No.:4192-90-9
- N1-Methyl-4-nitrobenzene-1,2-diamine
Catalog No.:BCC9070
CAS No.:41939-61-1
- MLR 1023
Catalog No.:BCC6232
CAS No.:41964-07-2
- Pinocembrin chalcone
Catalog No.:BCN7223
CAS No.:4197-97-1
- Glabranin
Catalog No.:BCN5480
CAS No.:41983-91-9
- (S)-(-)-Propranolol hydrochloride
Catalog No.:BCC6809
CAS No.:4199-10-4
- 5-Chloro-1,10-phenanthroline
Catalog No.:BCC3713
CAS No.:4199-89-7
Cardiac-protective effects and the possible mechanisms of alatamine during acute myocardial ischemia.[Pubmed:26863576]
Can J Physiol Pharmacol. 2016 Apr;94(4):433-40.
Alatamine is a constituent in the extract of a traditional herbal medicine Ramulus euonymi widely used for cardiac protection. However, its precise effects remain unclear. In the present study, we found that Alatamine was able to reduce acute myocardial ischemia (AMI)-induced cardiac dysfunction in a rat model, as reflected by significantly restored electrocardiograms, M-mode echocardiograms, and left ventricular hemodynamics. Also, Nagar Olsen staining revealed that Alatamine markedly reduced AMI-induced cardiac injury and cardiac myocyte apoptosis. TUNEL and caspase-3 activity assay showed that cardiac myocytes underwent significant apoptosis during AMI, and levels of LDH and CK-MB increased in the serum. However, such changes were significantly inhibited by pre-administration of Alatamine. Furthermore, such anti-apoptotic effects of Alatamine was also confirmed in a cardiac myocyte model of isoproterenol (ISO)-induced damage. Mechanistically, it was also found that Alatamine improved the expression and activity of sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase (SERCA), which were inhibited during AMI, promoting contractility and relaxation. Meanwhile, Alatamine decreased Bax and increased Bcl-2 expressions both in vivo and in vitro, therefore inhibiting cardiac myocyte apoptosis and preventing cardiac dysfunction caused by AMI at the cellular level. The present study revealed the beneficial role of Alatamine in cardiac protection and highlighted it as a potential therapeutic reagent for reduction of AMI-induced cardiac injury.
